Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib with Rituximab and Chemotherapy for R/R CNS B-Cell Lymphoma
NCT05926427Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Aug 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in central nervous system lymphoma, sponsored by Ruijin Hospital. Started Aug 2023; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT05926427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05926427.